{"id":"W2136541422","doi":"10.1016/s1470-2045(13)70380-2","title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":799,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Dexamethasone; Medicine; Lenalidomide; Refractory (planetary science); Internal medicine; Multiple myeloma; Clinical endpoint; Bortezomib; Population; Thalidomide; Progressive disease; Clinical trial; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08314179518883183,"score_gpt":0.3790846202528805,"score_spread":0.2959428250640487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}